Abstract
Insulin resistance underpins the development of type 2 diabetes and is the centre of the cluster of cardiovascular risk factors termed the insulin resistance syndrome. Increased cardiovascular risk is established in the prediabetic phase whereas the risk of microvascular complications is associated with overt diabetes. The success of monotherapy is usually partial and/or temporary. A new class of agents, the thiazoidinediones, addresses insulin resistance, targeting peroxisome proliferator-activated receptor gamma. These agents have considerable clinical potential.
| Original language | English |
|---|---|
| Journal | British Journal of Cardiology |
| Volume | 8 |
| Issue number | SUPPL. 4 |
| Publication status | Published - 1 Dec 2001 |
Keywords
- Cardiovascular risk
- Combination therapy
- Glycaemic control
- Insulin resistance
- Thiazolidinediones
- Type 2 diabetes